Table 4.
Non-susceptibility rates of the gram positive bacteria.
| Pathogen (n) | Antimicrobial non-susceptibility (%) | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| AMC | SXT | CAZ | CTX | CAF | NIT | CRT | E | AMP | GN | MER | AMK | |
| S. aureus (56) | 7 (12.5) | 17 (30.4) | 18 (32.2) | 3 (5.3) | 14 (25) | 6 (10.7) | 19 (34) | 29 (51.8) | 37 (66) | 31 (55.6) | 3 (5.3) | 12 (21.4) |
| CoNS (48) | 14 (29.2) | 22 (45.8) | 11 (22.9) | 7 (14.6) | 20 (41.7 | 6 (12.5) | 1 (2.1) | 24 (50) | 31 (64.5) | 20 (41.7) | 6 (12.5) | 9 (18.7) |
| Enterococci spp n = 7 | 1 (14.5) | 4 (57.2) | 4 (57.2) | 4 (57.2) | 2 (28.5) | 2 (28.5) | 1 (14.5) | 4 (57.2) | 4 (57.2) | 6 (85.7) | 1 (14.2) | 2 (28.5) |
| S. pyogens (n = 4) | 2 (50) | 2 (50) | 1 (25) | 1 (25) | 3 (75) | 0 | 1 (25) | 3 (75) | – | 3 (75) | 0 | 1 (25) |
CoNS, Coagulase Negative Staphylococci; AMC, Amoxicillin-Calvulanic acid (20/10 μg); SXT, cotrimoxazole (25 μg); CAZ, Ceftazidime (30 μg); CTX, cefotaxime(30 μg); CAF, Chloramaphenicol; NIT, nitrofurantoin (300 μg); CRT, ceftriaxone (30 μg); AMP, ampicillin (10 μg); E, Erythromycin (30 μg); GN, gentamicin (10 μg); MER, meropenem (10 μg); AMK, Amikacin (30 μg).